Moreover, excessive release of striatal dopamine appears to be the reason for the dysfunction of BGCTC in tic patients (33), and dopamine receptor D2 antagonists that can inhibit dopamine-induced effects represent the most efficacious pharmacotherapy of tics in clinic (34). This evidence concerns the gene DRD2 and tic disorder.